As a result of MANF being designated as an Orpha
Post# of 30028
Posted On: 12/23/2014 2:40:31 PM
Quote:
As a result of MANF being designated as an Orphan Drug, Amarantus is now entitled to certain R&D tax credits equivalent to 50% of the qualified clinical testing expenses for development, a waiver of PDUFA fees, access to government grants and contracts totalling $30 million per year, and seven years of market exclusivity post approval for the target indication.
Not bad...opens an excellent funding door....and that's only from one Orphan indication...
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼